On February 4, 2019 Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that its CEO, Dr. David Giljohann, will present at the Immuno-Oncology 360° Conference (IO360°) being held February 6-8, 2019 at the Crowne Plaza Times Square in New York City (Press release, Exicure, FEB 4, 2019, View Source [SID1234533037]). Dr. Giljohann’s presentation titled "Innate Immune System Activation with Spherical Nucleic Acids" will occur on Thursday, February 7, 2019 at 4:30 pm EST during the Translational Science & Emerging Biomarkers Part II track.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!